Overview

Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether giving azacitidine before each cycle of chemotherapy prior to surgery is safe.
Phase:
Phase 1
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
Celgene Corporation
Treatments:
Azacitidine
Capecitabine
Epirubicin
Oxaliplatin